Supernus Pharmaceuticals Inc
Research Supernus Pharmaceuticals Inc (SUPN) on Bullrun: market cap USD 1.52B, dividend yield 29.4%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSUPN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Market capUSD 1.52B
- Dividend yield29.4%
- Financial periodQ3 2026
- RevenueUSD 226.77M
- Net incomeUSD 20.91M
- Free cash flowUSD 6.38M
- Gross margin88.1%
Valuation Snapshot
latest market cap is USD 1.52B; dividend yield is 29.4%.
Peer valuation comparison
Latest dividend yield is 29.44% versus a Healthcare sector median of 2.39% (1131.8% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 718.95M | -USD 38.60M | USD 45.99M | 89.6% | -0.68 | USD 128.45M | USD 40.98M | USD 1.06B |
| FY2024 | USD 661.82M | USD 73.90M | USD 171.23M | 88.2% | 1.32 | USD 69.33M | USD 34.27M | USD 1.04B |
| FY2023 | USD 607.52M | USD 1.30M | USD 110.53M | 86.2% | 0.02 | USD 75.05M | USD 41.53M | USD 921.52M |
| FY2022 | USD 667.24M | USD 60.70M | USD 116.41M | 86.9% | 1.04 | USD 93.12M | USD 444.76M | USD 886.20M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-06 | USD 1.52B | n/a | 31.1% | 8.13 |
| 2025 | 2025-12-31 | USD 2.86B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.02B | 27.4 | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.58B | 74.2 | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.93B | 55.7 | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.55B | 29.8 | n/a | n/a |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 8.13 USD, yield 29.4%.
About Supernus Pharmaceuticals Inc
Supernus, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film.
ETFs that hold Supernus Pharmaceuticals Inc
US-listed ETFs
Supernus Pharmaceuticals Inc is held by 107 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| iShares Russell 2000 ETF (IWM) | 0.08% | 0.19% |
| Vanguard Morningstar Total Stock Market ETF (VTI) | <0.01% | 0.03% |
| iShares Core S&P Small-Cap ETF (IJR) | 0.15% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| Schwab U.S. Broad Market ETF (SCHB) | <0.01% | 0.03% |
| iShares Core S&P Total U.S. Stock Market ETF (ITOT) | <0.01% | 0.03% |
| Vanguard Russell 2000 Index Fund ETF Shares (VTWO) | 0.07% | 0.06% |
| iShares Russell 2000 Growth ETF (IWO) | 0.01% | 0.24% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Supernus Pharmaceuticals Inc's market cap?
Supernus Pharmaceuticals Inc's market capitalization is USD 1.52B.
Does Supernus Pharmaceuticals Inc pay a dividend?
Supernus Pharmaceuticals Inc has a dividend yield of 29.4%.
What does Supernus Pharmaceuticals Inc do?
Supernus, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film.